2025
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.Peer-Reviewed Original ResearchConceptsAcute leukemiaPhiladelphia chromosome-positive acute leukemiaRecommended phase 2 dosePh+ acute lymphoblastic leukemiaHematopoietic stem cell transplantationDe novo ALLHematologic remission rateLymphoid blast crisisMaximum tolerated doseStem cell transplantationPhase 1 studyChronic myeloid leukemiaMulticolor flow cytometryAcute lymphoblastic leukemiaVaso-occlusive eventsCytogenetic remissionBlast crisisSymptomatic pancreatitisTolerated doseRemission ratePh+ ALLCell transplantationMedian ageEnzyme elevationLymphoblastic leukemia
2024
Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
Chen E, Liu Y, Bell H, Galinsky I, Luskin M, Winer E, Stahl M, Vedula R, Volpe V, DeAngelo D, Quillen K, Ryan J, Minihane E, Hersch M, Leonard R, Neuberg D, Stone R, Letai A, Lane A, Garcia J. Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study. Blood 2024, 144: 4580-4580. DOI: 10.1182/blood-2024-198284.Peer-Reviewed Original ResearchAcute myeloid leukemiaAdvanced myeloid neoplasmsDose-limiting toxicityPhase 1 studyIncreased apoptotic primingMyeloid neoplasmsNavitoclax doseOverall survivalDNA methyltransferase inhibitorHematologic recoveryApoptotic primingTherapy-related acute myeloid leukemiaDose levelsHematologic dose-limiting toxicityHigh-risk myeloid neoplasmsRecommended phase 2 doseSecondary acute myeloid leukemiaNewly-diagnosed acute myeloid leukemiaResponse rateIncomplete hematologic recoveryPartial hematologic recoveryPhase 2 doseBCL2 inhibitor venetoclaxImmature platelet fractionMyelodysplastic syndrome/myeloproliferative neoplasmSafety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).
Khawaja M, Naqash A, Schneider R, Shastri A, Stahl M, Moser J, Abdel Karim N, Madanat Y, Jonas B, Stein E, Gadgeel S, McCloskey J, Gollerkeri A, Perea R, Chutake Y, Agarwal S, Henrick P, Shi K, Daver N. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). Journal Of Clinical Oncology 2024, 42: 3084-3084. DOI: 10.1200/jco.2024.42.16_suppl.3084.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaMouse double minute 2Arm BArm AAdverse eventsSolid tumorsOpen-label phase 1 studyMouse double minute 2 inhibitorUpregulated p53 activityDecreased oral intakeMerkel cell carcinomaAdenoid cystic carcinomaPhase 1 studySolid tumor typesAcute apoptotic responseDose-dependent increaseGDF-15 proteinPreclinical PDX modelsWild-type p53Anti-tumor activityDouble minute 2Upregulation of CDKN1AR/R AMLDose escalationTumor regression
2023
Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Winer E, Garcia J, Stone R, Wadleigh M, Luskin M, Stahl M, Chen E, Leonard R, Noyes A, Galinsky I, Deshpande R, Borderies P, O'Neill V, DeAngelo D. Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 2023, 142: 1549. DOI: 10.1182/blood-2023-186598.Peer-Reviewed Original ResearchRelapsed/refractory AMLHypomethylating agentsMetastatic castration-resistant prostate cancerCycles of HMARecommended phase 2 doseRelapsed/refractory acute myeloid leukemiaAllogeneic bone marrow transplantationCastration-resistant prostate cancerHigh-risk myelodysplastic syndromeNon-small cell lung cancerOral small-molecule inhibitorPhase 2 doseNon-Hodgkin's lymphomaDuration of responseMaximum tolerated doseECOG performance statusT cell responsesAdequate renal functionBone marrow transplantationAdequate liver functionPhase 1 studyCell lung cancerInduction of IL-18Acute myeloid leukemiaActivation of inflammatory cytokines
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply